Generation Bio to Present at the Jefferies Cell & Genetic Medicine Summit
September 19 2023 - 7:30AM
Generation Bio Co. (Nasdaq:GBIO), a biotechnology company
innovating genetic medicines for people living with rare and
prevalent diseases, announced that Geoff McDonough, M.D., president
and chief executive officer, will participate in a fireside chat at
the Jefferies Cell & Genetic Medicine Summit on Tuesday,
September 26, 2023 at 9:30 a.m. ET in New York.
A live webcast of the presentation will be
available on the investor section of the company’s website at
investors.generationbio.com. A replay will be available there for
30 days following the event.
About Generation
Bio Generation Bio is innovating genetic medicines
to provide durable, redosable treatments for people living with
rare and prevalent diseases. The company’s non-viral genetic
medicine platform incorporates a novel DNA construct called
closed-ended DNA, or ceDNA; a unique cell-targeted lipid
nanoparticle delivery system, or ctLNP; and a highly scalable
capsid-free manufacturing process that uses proprietary cell-free
rapid enzymatic synthesis, or RES, to produce ceDNA. This approach
is designed to enable multi-year durability from a single dose, to
deliver large genetic payloads, including multiple genes, to
specific tissues and cell types, and to allow titration and
redosing to adjust or extend expression levels in each patient. RES
has the potential to expand Generation Bio’s manufacturing scale to
hundreds of millions of doses to support its mission to extend the
reach of genetic medicine to more people, living with more
diseases, around the world. For more information, please
visit www.generationbio.com.
Investors and Media ContactMaren
KillackeyGeneration Biomkillackey@generationbio.com857-371-4638
Generation Bio (NASDAQ:GBIO)
Historical Stock Chart
From Apr 2024 to May 2024
Generation Bio (NASDAQ:GBIO)
Historical Stock Chart
From May 2023 to May 2024